ClinicalTrials.gg
CompletedNCT01063075Updated Sep 26, 2019Results posted

A Study in Advanced Solid Tumors

A Phase 2 interventional study of Cetuximab and Carboplatin in Solid Tumor, sponsored by Eli Lilly and Company. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Head and Neck Neoplasms — 2 open to participants now, 7 under way, 2 of them phase 3. Cetuximab · Head and Neck Neoplasms.

Enrollment
48th of 84
34 · median 37
Started
2010
with 11 others
Phase 2
52 of 86
1 open now
Registered
46th of 86
by date
Lead sponsor
5 of 86
Eli Lilly and Company

Among the 86 studies testing cetuximab in Head and Neck Neoplasms, this one is the 48th largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2010, is one of 52 in phase 2, and was the 46th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

2 of the 86 studies testing cetuximab in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of this study is to help answer the following research question(s):

  • To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with carboplatin [pharmacokinetic (PK) analysis]
  • To see if any drug interactions occur between cetuximab and carboplatin.
03

Conditions studied

  • Solid Tumor

Keywords

  • Cancer of Head
  • Cancer of Head and Neck
  • Cancer of Neck
  • Head and Neck Cancer
  • Head Cancer
  • Head Neoplasms
  • Head, Neck Neoplasms
  • Neck Cancer
  • Neck Neoplasms
  • Solid Neoplasm
  • Carcinoma
  • Sarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has or cytologically confirmed advanced solid tumor that is resistant to standard therapy or for which there is no standard therapy.
  • The participant has measurable or non- according to 1.0 guidelines.
  • The participant has a of greater than 3 months.
  • The participant has an (ECOG) performance status of 0, 1, or 2.
  • The participant has adequate hematologic function as defined by greater than or equal to 1500/microliter (μL), greater than or equal to 9 grams/deciliter (g/dL), and count greater than or equal to 100,000/μL.
  • The participant has adequate hepatic function as defined by a total less than or equal to 2 x the (ULN), (AST, SGOT) and alanine transaminase (ALT, SGPT) less than or equal to 3 x the ULN (or less than or equal to 5 x the ULN in the presence of known liver ).
  • The participant has adequate renal function as defined by serum creatinine less than or equal to 1.5 x the institutional ULN or greater than or equal to 60 mL/min for participants with creatinine levels above the ULN.
  • The participant has the ability to understand, and the willingness to sign, a written document.
  • If the participant has received prior therapy with platinum, the time to the first treatment of study drug from the last platinum exposure is >28 days.

Exclusion criteria

Exclusion Criteria:

  • The participant has symptomatic brain or .
  • The participant has not recovered from adverse events due to agents administered more than 4 weeks earlier. Neurotoxicity, if present, must have improved to Grade less than 2 per the National Cancer Institute - (NCI-CTCAE) v 3.0.
  • The participant is receiving any other agent(s).
  • The participant is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy,radiation therapy ( RT), chemoembolization, or targeted therapy. Participants receiving palliative radiation therapy to bony prior to the first dose of study medication are eligible.
  • The participant is receiving therapy with agents.
  • The participant has known drug or alcohol abuse.
  • The participant has uncontrolled hypertension defined as systolic blood pressure greater than or equal to 180 millimeters of mercury (mm Hg) or diastolic blood pressure greater than or equal to 130 mm Hg.
  • The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or carboplatin.
  • The participant has a medical or psychological condition that would not permit the participant to complete the study or sign .
  • The participant has coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency.
  • The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [β-HCG] pregnancy test) or breastfeeding
  • The participant has had a known positive test result for the .
  • The participant has an active infection (requiring I.V antibiotics), including tuberculosis.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cetuximab and Carboplatin (D)

    Group D: Cycle 1 (1 week, combination therapy): 400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1. After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. After protocol amendment February 2014, any newly enrolled participants were placed into Group D only.

    Drug: Cetuximab · Drug: Carboplatin · Drug: 5 - FU

  • Experimental
    Cetuximab and Carboplatin (C)

    Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1. Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1. After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only.

    Drug: Cetuximab · Drug: Carboplatin · Drug: 5 - FU

  • Experimental
    Cetuximab and Carboplatin (B)

    Group B: Cycle 1 (3 weeks, single-agent cetuximab): 400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1. Cycle 2 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1. After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only.

    Drug: Cetuximab · Drug: Carboplatin · Drug: 5 - FU

  • Experimental
    Carboplatin and Cetuximab (A)

    Group A: Cycle 1 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1. Cycle 2 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1. After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only.

    Drug: Cetuximab · Drug: Carboplatin · Drug: 5 - FU

Interventions

06

What researchers measure

Primary outcomes

  1. Total Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞])

    Time frame: Group D: Cycle 1, Week 1, Day 1; Prior to Carboplatin Infusion, 1hour (H), 1:30 H, 2 H, 3 H, 5 H, 8 H, 24 H, 72 H (after the Start of Carboplatin Infusion)

  2. Cetuximab PK: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC τ,ss)

    Time frame: (Group B: Cycle 1 and Cycle 2+ ; Day 1, 8, 15 and Group C: Cycle 1, Day 8, 15 and 22; Cycle 2+, Day 1,8 and 15): Prior to Cetuximab Infusion, 1 Hour (H), 2 H, 4 H, 8 H, 24 H, 72 H, 120 H, and 168 H (after the start of Cetuximab Infusion)

  3. Total Carboplatin PK: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Group D: Cycle 1, Week 1, Day 1; Prior to Carboplatin Infusion, 1hour (H), 1:30 H, 2 H, 3 H, 5 H, 8 H, 24 H, 72 H (after the Start of Carboplatin Infusion)

  4. Cetuximab PK: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)

    Time frame: (Group B: Cycle 1 and Cycle 2+ ; Day 1, 8, 15 and Group C: Cycle 1, Day 8, 15 and 22; Cycle 2+, Day 1,8 and 15): Prior to Cetuximab Infusion, 1 Hour (H), 2 H, 4 H, 8 H, 24 H, 72 H, 120 H, and 168 H (after the start of Cetuximab Infusion)

  5. Total Carboplatin PK: Time of Maximum Observed Plasma Concentration (Tmax)

    Time frame: Group D: Cycle 1, Week 1, Day 1; Prior to Carboplatin Infusion, 1hour (H), 1:30 H, 2 H, 3 H, 5 H, 8 H, 24 H, 72 H (after the Start of Carboplatin Infusion)

  6. Cetuximab PK: Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss)

    Time frame: (Group B: Cycle 1 and Cycle 2+ ; Day 1, 8, 15 and Group C: Cycle 1, Day 8, 15 and 22; Cycle 2+, Day 1,8 and 15): Prior to Cetuximab Infusion, 1 Hour (H), 2 H, 4 H, 8 H, 24 H, 72 H, 120 H, and 168 H (after the start of Cetuximab Infusion)

  7. Cetuximab PK: Confirmatory Serum Concentration

    Time frame: Group D: Prior to Carboplatin Infusion, Cycle 1, Day 1

07

Results

Posted Jun 15, 2016
Limitations and caveats
Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin(C) arm only. After protocol amendment February 2014, any newly enrolled participants were placed into Group D arm only.

Participant flow

Participant flow — Overall Study
MilestoneCarboplatin and Cetuximab (A)Cetuximab and Carboplatin (B)Cetuximab and Carboplatin (C)Cetuximab and Carboplatin (D)
Started231415
Completed11914
Not completed1251

Outcome measures

PrimaryTotal Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞])
Time frame:
Group D: Cycle 1, Week 1, Day 1; Prior to Carboplatin Infusion, 1hour (H), 1:30 H, 2 H, 3 H, 5 H, 8 H, 24 H, 72 H (after the Start of Carboplatin Infusion)
Reported as:
Geometric mean · micrograms*hour/milliliters (μg•h/mL)
Total Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞])
micrograms*hour/milliliters (μg•h/mL)Cetuximab and Carboplatin (D)
Total Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞])129 ± 14.8
PrimaryCetuximab PK: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC τ,ss)
Time frame:
(Group B: Cycle 1 and Cycle 2+ ; Day 1, 8, 15 and Group C: Cycle 1, Day 8, 15 and 22; Cycle 2+, Day 1,8 and 15): Prior to Cetuximab Infusion, 1 Hour (H), 2 H, 4 H, 8 H, 24 H, 72 H, 120 H, and 168 H (after the start of Cetuximab Infusion)
Reported as:
Geometric mean · micrograms*hour/milliliters (μg•h/mL)
Cetuximab PK: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC τ,ss)
micrograms*hour/milliliters (μg•h/mL)Cetuximab (B and C)Cetuximab and Carboplatin (B and C)
Cetuximab PK: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC τ,ss)17200 ± 15.816700 ± 18.5
PrimaryTotal Carboplatin PK: Maximum Observed Plasma Concentration (Cmax)
Time frame:
Group D: Cycle 1, Week 1, Day 1; Prior to Carboplatin Infusion, 1hour (H), 1:30 H, 2 H, 3 H, 5 H, 8 H, 24 H, 72 H (after the Start of Carboplatin Infusion)
Reported as:
Geometric mean · micrograms per milliliters (μg/mL)
Total Carboplatin PK: Maximum Observed Plasma Concentration (Cmax)
micrograms per milliliters (μg/mL)Cetuximab and Carboplatin (D)
Total Carboplatin PK: Maximum Observed Plasma Concentration (Cmax)11.5 ± 15.8
PrimaryCetuximab PK: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)
Time frame:
(Group B: Cycle 1 and Cycle 2+ ; Day 1, 8, 15 and Group C: Cycle 1, Day 8, 15 and 22; Cycle 2+, Day 1,8 and 15): Prior to Cetuximab Infusion, 1 Hour (H), 2 H, 4 H, 8 H, 24 H, 72 H, 120 H, and 168 H (after the start of Cetuximab Infusion)
Reported as:
Geometric mean · micrograms per milliliters (μg/mL)
Cetuximab PK: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)
micrograms per milliliters (μg/mL)Cetuximab (B and C)Cetuximab and Carboplatin (B and C)
Cetuximab PK: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)199 ± 10.3199 ± 10.8
PrimaryTotal Carboplatin PK: Time of Maximum Observed Plasma Concentration (Tmax)
Time frame:
Group D: Cycle 1, Week 1, Day 1; Prior to Carboplatin Infusion, 1hour (H), 1:30 H, 2 H, 3 H, 5 H, 8 H, 24 H, 72 H (after the Start of Carboplatin Infusion)
Reported as:
Median · Hour (h)
Total Carboplatin PK: Time of Maximum Observed Plasma Concentration (Tmax)
Hour (h)Cetuximab and Carboplatin (D)
Total Carboplatin PK: Time of Maximum Observed Plasma Concentration (Tmax)1.12 (1.00 to 1.30)
PrimaryCetuximab PK: Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss)
Time frame:
(Group B: Cycle 1 and Cycle 2+ ; Day 1, 8, 15 and Group C: Cycle 1, Day 8, 15 and 22; Cycle 2+, Day 1,8 and 15): Prior to Cetuximab Infusion, 1 Hour (H), 2 H, 4 H, 8 H, 24 H, 72 H, 120 H, and 168 H (after the start of Cetuximab Infusion)
Reported as:
Median · Hour (h)
Cetuximab PK: Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss)
Hour (h)Cetuximab (B and C)Cetuximab and Carboplatin (B and C)
Cetuximab PK: Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss)1.15 (1.02 to 7.83)3.17 (2.00 to 4.07)
PrimaryCetuximab PK: Confirmatory Serum Concentration
Time frame:
Group D: Prior to Carboplatin Infusion, Cycle 1, Day 1
Reported as:
Geometric mean · micrograms per milliliters (µg/mL)
Cetuximab PK: Confirmatory Serum Concentration
micrograms per milliliters (µg/mL)Cetuximab (D)
Cetuximab PK: Confirmatory Serum Concentration195 ± 16.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboplatin and Cetuximab (A)—1/2 (50%)2/2 (100%)
Carboplatin and Cetuximab (B)—1/3 (33.3%)2/3 (66.7%)
Carboplatin and Cetuximab (C)—5/14 (35.7%)14/14 (100%)
Carboplatin and Cetuximab (D)—10/15 (66.7%)15/15 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCarboplatin and Cetuximab (A)Carboplatin and Cetuximab (B)Carboplatin and Cetuximab (C)Carboplatin and Cetuximab (D)
Non-cardiac chest painGeneral disorders1/20/30/140/15
SeizureNervous system disorders1/20/30/140/15
HaematuriaRenal and urinary disorders1/20/30/141/15
DyspnoeaRespiratory, thoracic and mediastinal disorders1/20/30/140/15
HypokalaemiaMetabolism and nutrition disorders0/21/30/140/15
LethargyNervous system disorders0/21/30/140/15
Urinary tract infectionInfections and infestations0/20/30/142/15
AnaemiaBlood and lymphatic system disorders0/20/31/140/15
LeukopeniaBlood and lymphatic system disorders0/20/31/140/15
NeutropeniaBlood and lymphatic system disorders0/20/31/140/15
Most frequent other events
Showing 10 of 181
Most frequent other events
EventCarboplatin and Cetuximab (A)Carboplatin and Cetuximab (B)Carboplatin and Cetuximab (C)Carboplatin and Cetuximab (D)
NauseaGastrointestinal disorders0/21/311/148/15
StomatitisGastrointestinal disorders0/22/35/144/15
VomitingGastrointestinal disorders0/22/36/145/15
FatigueGeneral disorders1/22/37/149/15
Haemoglobin decreasedInvestigations0/22/30/140/15
HypokalaemiaMetabolism and nutrition disorders0/21/33/149/15
Dermatitis acneiformSkin and subcutaneous tissue disorders1/20/37/149/15
DiarrhoeaGastrointestinal disorders1/21/38/143/15
AnaemiaBlood and lymphatic system disorders1/20/34/146/15
ConstipationGastrointestinal disorders1/21/35/142/15

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)All Participants (Group A, B, C and D)
Mean58.20 ± 12.88
Sex: Female, Male
Sex: Female, Male(Participants)All Participants (Group A, B, C and D)
Female8
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants (Group A, B, C and D)
Hispanic or Latino0
Not Hispanic or Latino34
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants (Group A, B, C and D)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White31
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)All Participants (Group A, B, C and D)
Canada10
United States24
08

Study locations

8 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • University of Kansas Medical Center
    Fairway, Kansas 66205, United States
  • Portland VA Medical Center
    Portland, Oregon 91239, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6A 4L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H3G 1A4, Canada
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of May 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2010
First posted
Feb 5, 2010
Start
Jun 2010
Primary completionActual
May 2015
CompletionActual
Oct 2015
Results first posted
Jun 15, 2016
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01063075
Responsible party
Sponsor
First posted
Feb 5, 2010
Start date
Jun 2010
Primary completion
May 2015
Completion
Oct 2015
Results posted
Jun 15, 2016
Last update
Sep 26, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Carboplatin

Start the discussion